Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 13/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11313043 | 0.98 | EPHX2 (0.56) | EPHX2EPHX1CYP1A2TDP1MAPT | |
| SCHEMBL13446743 | 0.89 | EPHX2 (0.49) | EPHX2EPHX1 | |
| SCHEMBL14586756 | 0.89 | EPHX2 (0.49) | EPHX2EPHX1MAPT | |
| Trifluoroacetic Acid SCHEMBL26599559 | 0.87 | EPHX2 (0.47) | EPHX2EPHX1 | |
| SCHEMBL12225565 | 0.87 | EPHX2 (0.50) | EPHX2EPHX1MAPT | |
| SCHEMBL961566 | 0.87 | EPHX2 (0.50) | EPHX2EPHX1MAPT | |
| SCHEMBL12820400 | 0.87 | EPHX2 (0.50) | EPHX2EPHX1MAPT | |
| SCHEMBL10156619 | 0.84 | ALDH1A1 (0.52) | EPHX2EPHX1 | |
| SCHEMBL3317493 | 0.82 | EPHX2 (0.58) | EPHX2EPHX1CYP1A2TDP1MAPT | |
| SCHEMBL111634 | 0.82 | EPHX2 (0.40) | EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436178-B2 | Imidazoquinolines with immuno-modulating properties | ASTRAZENECA AB (SE) | 2013-05-07 | — | — | US | claimed |
| US-8324257-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-12-04 | — | — | US | claimed |
| EP-2155743-B1 | IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES | ASTRAZENECA AB (SE) | 2012-08-29 | — | — | EP | claimed |
| US-20100280001-A1 | IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2010-11-04 | — | — | US | claimed |
| US-20100041719-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-02-18 | — | — | US | claimed |
| CN-101553476-A | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2009-10-07 | — | — | CN | claimed |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-25 | — | — | US | disclosed |
| WO-2024134466-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS, SUBSTITUTED HETEROARYLAMINE COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-27 | — | — | WO | disclosed |
| US-11992494-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-05-28 | — | — | US | disclosed |
| WO-2024069448-A1 | SUBSTITUTED 1-ARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1-HETEROARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-04-04 | — | — | WO | disclosed |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| EP-4313968-A2 | SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2024-02-07 | — | — | EP | disclosed |
| US-5773530-A | USEFUL AS PSYCHOSTIMULANTS, ANTIHYPERTENSIVE AGENTS AND REMEDIES FOR RENAL FAILURE, DIURETICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
| EP-0457686-B1 | Novel aminopiperidine, aminopyrrolidine and aminoperhydroazepine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1994-08-03 | — | — | EP | disclosed |
| US-5214055-A | Analgesics, psychological disorders, anxiolytic agents | ADIR ET COMPAGNIE (FR) | 1993-05-25 | — | — | US | disclosed |
| US-5189045-A | Antiserotonine agent | ADIR ET COMPAGNIE (FR) | 1993-02-23 | — | — | US | disclosed |
| CN-1019393-B | Substituted N-[(4-piperidingl] alkyl] bicyclic condensed oxazol and thiazolaminer | JANSSEN PHARMACEUTICA NV (BE) | 1992-12-09 | — | — | CN | disclosed |
| EP-0457686-A1 | Novel aminopiperidine, aminopyrrolidine and aminoperhydroazepine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1991-11-21 | — | — | EP | disclosed |
| US-4289772-A | PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 1981-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280001-A1 | IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES | IFNG, FCGRT, IFNAR1 | EPHX2 2052/4885EPHX1 573/4885CYP1A2 237/4885 |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | EPHX2 3938/4885EPHX1 3641/4885CYP1A2 4577/4885 |
| US-11992494-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | PTAFR, PDGFRA, PDGFRB | EPHX2 1805/4885EPHX1 894/4885CYP1A2 1216/4885 |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | EPHX2 3938/4885EPHX1 3641/4885CYP1A2 4577/4885 |
| US-20100041719-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIF18B | EPHX2 3595/4885EPHX1 3193/4885CYP1A2 4426/4885 |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | HAVCR2, HDGF, HCCS | EPHX2 1434/4885EPHX1 931/4885CYP1A2 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.